Fig. 1 · Structure

Documents & Downloads

Timapiprant (OC 000459)

Cat. No. A11946 CAS 851723-84-7

CRTH2 antagonist

OC 000459 is a potent, oral and selective CRTH2 (also known as DP2) antagonist.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
CHO-K1 IC50 130 nM Antagonist activity at CRTh2 receptor (unknown origin) overexpressed in CHOK1 cell membranes assessed as inhibition of [35S]-GTPgammaS binding preincubated for 1 hr followed by 50 nM PGD2 and 0.1 nM [35S]-GTPgammaS addition measured after 2 hrs by liquid [PMID: 23601708]

Timapiprant (OC 000459) Research Summary

This section summarizes 4 in vivo studies of Timapiprant (OC 000459) from 3 published references. In vivo models include 11-mo-old Tg-AD.

Timapiprant (OC 000459) In Vivo Studies

In Tg-AD rats, Timapiprant administered orally in rodent chow significantly mitigated Aβ plaque load in the hippocampal DG hilar subregion. In the laser-induced CNV mouse model, subcutaneous Timapiprant (OC000459) produced significantly smaller CNV sizes than vehicle. In mice undergoing caerulein intervention, daily i.p. Timapiprant (OC000459) treatment resulted in significantly less fibrotic tissue than vehicle. In Tg-AD rats, oral Timapiprant also alleviated neuronal loss in the GCL subregion. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Reduced hippocampal amyloid plaque burden in Tg-AD rats

Animal study · 11-mo-old Tg-AD [1]

Tg-AD rats received Timapiprant orally in rodent chow at 15 mg/kg body weight/day/rat for 4 mo. Treatment significantly mitigated Aβ plaque load in the hippocampal DG hilar subregion compared with untreated Tg-AD rats.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Aβ plaque burden in the hippocampal DG hilar subregionReported result 15 mg/kg body weight/day/rat administered orally in rodent chow (Research Diets Inc.) for 4 mo: timapiprant significantly mitigated Aβ plaque load (Fig 10, t = 3.55, P = 0.001, and Fig 10).[1]

Conditions shared by the study groups

Route
administered orally in rodent chow
Treatment course
At 7 mo; for 4 mo
Vehicle
rodent chow (Research Diets Inc.)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Timapiprant 15 mg/kg body weight/day/ratTg-AD non-treated (TGNT, n = 9) male rats15 mg/kg body weight/day/rat administered orally in rodent chow (Research Diets Inc.) for 4 mo: timapiprant significantly mitigated Aβ plaque load (Fig 10, t = 3.55, P = 0.001, and Fig 10).[1]
Timapiprant 15 mg/kg body weight/day/rat
Model: 11-mo-old Tg-AD
Methods and source locations

Compound reported in the paper: Timapiprant

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Timapiprant improves spatial learning and mitigates plaque burden, neuronal loss, and microgliosis in Tg-AD rats (S98, S103); Materials and Methods > Experimental design (S118, S119); Figure 10. legend (S286)

Aβ plaque burden in the hippocampal DG hilar subregion: Aβ plaque burden in the hippocampal DG hilar subregion; comparator: Tg-AD non-treated (TGNT, n = 9) male rats — Results > Timapiprant improves spatial learning and mitigates plaque burden, neuronal loss, and microgliosis in Tg-AD rats (S103); Materials and Methods > Experimental design (S119)

Timapiprant 15 mg/kg body weight/day/rat · Results > Timapiprant improves spatial learning and mitigates plaque burden, neuronal loss, and microgliosis in Tg-AD rats (S103); Materials and Methods > Experimental design (S118, S119)

Reduced lesion size in laser-induced choroidal neovascularization

Animal study · Male C57BL/6 mice; laser-induced CNV model; n = 79 spots of 16 eyes [2]

Male mice with laser-induced CNV received subcutaneous Timapiprant (OC000459) at 2 mg/mL. CNV sizes were significantly smaller than in the vehicle group at 7 days after laser photocoagulation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
The CNV sizes; at 7 days after laser photocoagulationReported result OC000459 (2 mg/mL, n = 79 spots of 16 eyes): significantly smaller than those in the control group; **P < 0.01.[2]

Conditions shared by the study groups

Route
subcutaneous administration
Treatment course
from 1 day before CNV induction; for 7 days
Vehicle
1:100 DMSO in PBS
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Timapiprant 2 mg/mL; 1.2 mg/day/kgvehicle groups (n = 74 spots of 17 eyes)OC000459 (2 mg/mL, n = 79 spots of 16 eyes): significantly smaller than those in the control group; **P < 0.01.[2]
Timapiprant 2 mg/mL; 1.2 mg/day/kg
Model: Male C57BL/6 mice; laser-induced CNV model; n = 79 spots of 16 eyes
Methods and source locations

Compound reported in the paper: Timapiprant; Compound label in the paper: OC000459

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Animals (S1); Methods > Induction of CNV (S5); Methods > Measurement of CNV Size and Immunohistochemistry (S9); Methods > DP2 Antagonist Administration (S14, S15, S16); Results (S59, S60); Figure 2. legend (S84, S85)

The CNV sizes; at 7 days after laser photocoagulation: The CNV sizes; at 7 days after laser photocoagulation; comparator: vehicle groups (n = 74 spots of 17 eyes) — Results (S59, S60); Figure 2. legend (S84)

Timapiprant 2 mg/mL; 1.2 mg/day/kg · Methods > DP2 Antagonist Administration (S16); Results (S59, S60); Figure 2. legend (S85)

Reduced fibrotic tissue in caerulein-treated mice

Animal study · C57Bl/6 mice; Veh. n = 8/OC n = 8 [3]

In the caerulein intervention model, mice received Timapiprant (OC000459) at 30 µg i.p. once daily. Treated mice had significantly less fibrotic tissue than vehicle-treated mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Quantification by pattern quant softwareReported result daily 30 µg of OC000459: significantly less fibrotic tissue in OC000459 treated mice (p = 0.0397, Veh. n = 8/OC n = 8).[3]

Conditions shared by the study groups

Route
i.p.
Treatment course
once daily
Vehicle
0.625% DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Timapiprant 30 µgvehicle (0.625% DMSO)daily 30 µg of OC000459: significantly less fibrotic tissue in OC000459 treated mice (p = 0.0397, Veh. n = 8/OC n = 8).[3]
Timapiprant 30 µg
Model: C57Bl/6 mice; Veh. n = 8/OC n = 8
Methods and source locations

Compound reported in the paper: Timapiprant; Compound label in the paper: OC000459

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Animal model (S163, S169); Methods > Histology, immunohistochemistry, and immunofluorescence (S198); Fig. 4 legend (S259, S260)

Quantification by pattern quant software: Quantification by pattern quant software; comparator: vehicle (0.625% DMSO) — Fig. 4 legend (S260)

Timapiprant 30 µg · Methods > Animal model (S169); Fig. 4 legend (S260)

Alleviated neuronal loss in Tg-AD rats

Animal study · 11-mo-old Tg-AD [1]

Tg-AD rats received Timapiprant orally in rodent chow at 15 mg/kg body weight/day/rat for 4 mo. Treatment alleviated neuronal loss in the GCL subregion.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
neuronal loss in the GCL subregionReported result 15 mg/kg body weight/day/rat administered orally in rodent chow (Research Diets Inc.) for 4 mo: timapiprant alleviated neuronal loss in the GCL subregion (Fig 10, t = 2.56, P = 0.01).[1]

Conditions shared by the study groups

Route
administered orally in rodent chow
Treatment course
At 7 mo; for 4 mo
Vehicle
rodent chow (Research Diets Inc.)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Timapiprant 15 mg/kg body weight/day/ratTg-AD non-treated (TGNT, n = 9) male rats15 mg/kg body weight/day/rat administered orally in rodent chow (Research Diets Inc.) for 4 mo: timapiprant alleviated neuronal loss in the GCL subregion (Fig 10, t = 2.56, P = 0.01).[1]
Timapiprant 15 mg/kg body weight/day/rat
Model: 11-mo-old Tg-AD
Methods and source locations

Compound reported in the paper: Timapiprant

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Timapiprant improves spatial learning and mitigates plaque burden, neuronal loss, and microgliosis in Tg-AD rats (S98, S104); Materials and Methods > Experimental design (S118, S119); Figure 10. legend (S286)

neuronal loss in the GCL subregion: neuronal loss in the GCL subregion; comparator: Tg-AD non-treated (TGNT, n = 9) male rats — Results > Timapiprant improves spatial learning and mitigates plaque burden, neuronal loss, and microgliosis in Tg-AD rats (S104); Materials and Methods > Experimental design (S119)

Timapiprant 15 mg/kg body weight/day/rat · Results > Timapiprant improves spatial learning and mitigates plaque burden, neuronal loss, and microgliosis in Tg-AD rats (S104); Materials and Methods > Experimental design (S118, S119)

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 851723-84-7
Applications CRTH2 antagonist
Formula C21H17FN2O2
Molecular Weight 348.4
Synonyms OC000459
SMILES
CC1=C(C2=C(N1CC(=O)O)C=CC(=C2)F)CC3=NC4=CC=CC=C4C=C3

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 4 mg/mL (11.48 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Timapiprant (OC 000459) Research References

  1. [1] Wallace CH, Oliveros G, Serrano PA, et al. Timapiprant, a prostaglandin D2 receptor antagonist, ameliorates pathology in a rat Alzheimer's model. Life Sci Alliance (2022). PMID: 36167438 DOI: 10.26508/lsa.202201555 Source material
  2. [2] Soga H, Inoue T, Urade Y, et al. Attenuation of Laser-Induced Choroidal Neovascularization by Blockade of Prostaglandin D2 Receptor 2. Transl Vis Sci Technol (2023). PMID: 37133840 DOI: 10.1167/tvst.12.5.5 Source material
  3. [3] Glaubitz J, Wilden A, Golchert J, et al. In mouse chronic pancreatitis CD25+FOXP3+ regulatory T cells control pancreatic fibrosis by suppression of the type 2 immune response. Nat Commun (2022). PMID: 35922425 DOI: 10.1038/s41467-022-32195-2 Source material

Added to your cart

View Cart Checkout
Loading...